###### Strengths and limitations of this study

-   Full protocol published in advance of data collection on PROSPERO.

-   Extensive searches including grey literature and handsearching.

-   Only English language results (or those where a translation was available) were reviewed.

Background {#s1}
==========

Description of the condition {#s1a}
----------------------------

The lifetime incidence of renal calculi (kidney stones) is ∼12% in males and 6% in females[@R1] with a peak between 40 and 60 years of age.[@R2] Renal colic is the pain experienced by a patient when a renal calculus causes partial or complete obstruction of part of the renal outflow tract. Pain in renal colic is caused by ureteric spasm with increased peristalsis around the stone and dilation of the proximal urinary tract. Local irritation with prostaglandin release and inflammation further increases the renal pelvic pressure.[@R3]

The clinical need that prompted this systematic review {#s1b}
------------------------------------------------------

Current analgesic regimes, usually involving a non-steroidal anti-inflammatory drug (NSAID)±an opiate,[@R2] are often suboptimal; in some studies, less than half of the patients achieve complete pain relief within an acceptable time frame and a large proportion of patients require rescue analgesia within 4 hours. Additionally, side effects (especially vomiting) are relatively common with opioid analgesia.[@R4]

Description of the intervention {#s1c}
-------------------------------

β-Adrenoreceptor agonists (β-agonists) such as salbutamol/albuterol (a selective β~2~-agonist[@R5] in common use) are used as a treatment for acute exacerbations of asthma in both its nebulised and intravenous forms. The mechanism of action is via smooth muscle relaxation and subsequent reduction in bronchospasm. Salbutamol is an extensively used, well-established treatment with an established safety profile which is also licensed for tocolysis in premature labour.[@R6]

How the intervention might work {#s1d}
-------------------------------

Various adrenoreceptor subtypes are present in the human ureter and their utility in the management of ureteral pathology is an area of scientific interest.

The α-adrenoreceptors present in the ureter mediate ureteral contraction;[@R7] their blockade reduces the time taken for ureteral stone passage, as well as reducing the frequency of pain episodes associated with renal colic.[@R8]

There is a body of laboratory evidence that β~2~-adrenoreceptor and β~3~-adrenoreceptor are expressed in the human ureter[@R9] and that their stimulation mediates ureteral relaxation.[@R9] It has been demonstrated in animal models that intravenous isoproterenol results in a decrease in ureteral activity.[@R14] Danuser *et al*[@R18] demonstrated that both intravenous and topical isoproterenol reduced the frequency of ureteral contractions to 13% and 31% of controls, respectively. Recently, Jung *et al*[@R19] achieved a reduction in renal pelvic pressure using endoluminal isoproterenol during ureterorenoscopic irrigation in human participants.

As yet, there is no direct evidence to inform the use of β-agonists as analgesic adjuncts in the treatment of pain associated with renal colic. It has been hypothesised[@R20] [@R21] that they may alleviate pain in patients with renal colic via ureteral relaxation mediated through β-adrenoreceptor stimulation. It is also worth noting that some β-agonists (eg, salbutamol) are at least partly excreted, unchanged, in the urine;[@R22] as such, the potential for systemic and topical action exists.

Objectives {#s2}
==========

The primary objective of this systematic review was to determine whether β-agonists are effective analgesics for patients with renal colic. Secondary objectives include identifying any effect that β-agonists may have on length of hospital stay or alternative analgesic requirement. We also sought to determine any effect that the impact of stone presence, size and position, and the degree of hydronephrosis, may have on the efficacy of β-agonists as analgesics.

Outcomes---primary {#s2a}
------------------

Level of pain (assessed by any validated quantitative method) at 30 min following administration of the β-agonist.

Outcomes---secondary {#s2b}
--------------------

A.  Level of pain, assessed by any validated quantitative method---where possible data were to be extracted at 60 min, 120 min, 240 min, 8 hours, 12 hours, 16 hours and 24 hours following administration of the β-agonist.

B.  Length of stay in hospital (days).

C.  Analgesic requirement, including medication used and cumulative dosage.

D.  Stone presence, size and position as determined by radiological investigation.

E.  Degree of hydronephrosis (expressed within any established grading system).

Methods {#s3}
=======

Protocol and registration {#s3a}
-------------------------

The protocol for this systematic review has been prospectively registered on PROSPERO. It can be found at the following web address: <http://www.crd.york.ac.uk/PROSPERO/display_record.asp?ID=CRD42015016266#.VVNR7tNVhBc>

The protocol registration number is CRD42015016266.

Study eligibility criteria {#s3b}
--------------------------

We searched for randomised, quasi-randomised, case-control and cohort clinical trials that fulfilled the following criteria: Patients---human participants with either proven or suspected renal colicInterventions---β-adrenoreceptor agonistsComparator---any of: placebo; alternative analgesic regimeOutcomes---any of: level of pain, assessed by any quantitative method; length of hospital stay; analgesic requirement; stone presence, size and position; degree of hydronephrosis

Lower level evidence such as case series or expert opinion pieces was not included within this systematic review. The background information discussed above provides adequate justification for considering the use of β-agonists in renal colic; as such, further expert opinion was not felt relevant to the study question. Case series alone would not provide adequate justification for changing practice and as such were excluded from the search results.

Information sources {#s3c}
-------------------

The following databases were searched: The Cochrane Database of Systematic Reviews (The Cochrane Library, issue 4, 2016)MEDLINE (via OVID) (from January 1980 until 27 April 2016)EMBASE (via OVID) (from January 1980 until 27 April 2016)The NCBI PubMed database <http://www.ncbi.nlm.nih.gov/pubmed>---searched 27 April 2016Centre for Reviews and Dissemination (CRD) <http://www.crd.york.ac.uk/CRDWeb/> including the databases Database of Abstracts of Reviews of Effects (DARE), Health Technology Assessments (HTA) and NHS Economic Evaluation Database (NHS EED)

Note: At the time of searching and write-up, the following information was made available by DARE:"'Bibliographic records will be published on DARE and NHS EED until 31st March 2015. NIHR funding to produce DARE and NHS EED ceases at the end of March 2015. However, both databases can be accessed via the CRD website. The HTA database will continue to be produced by CRD for the foreseeable future'."

We restricted the results of our search to those involving human participants and those either written in English, with an English abstract or with an English translation provided (due to a lack of available funding for translation services). We did not restrict the date range of the results and incorporated both thesaurus headings and keyword searching.

References and conference abstracts were searched by hand and any suitable papers identified and reviewed.

We searched the following sources for existing guidelines that may have contained applicable information: National Institute for Health and Care Excellence (NICE)Turning Research into Practice (TRIP)National Guideline ClearinghouseGuidelines identified in the already-mentioned databases (MEDLINE, EMBASE, etc)

We searched the UK Clinical Trials Gateway[@R23] and the National Institute for Health Research Clinical Research Network (NIHR CRN) Portfolio database[@R24] for details of ongoing trials in the UK. Other ongoing trials will be searched via ClinicalTrials.gov,[@R25] WHO International Clinical Trials Registry Platform (ICTRP) and Cochrane\'s CENTRAL database.

Any possible registered Systematic Reviews were searched for via PROSPERO (International Prospective Register of Systematic Reviews).

Relevant conference proceedings (Royal College of Emergency Medicine Annual Scientific Conference 2012--2014; European Society of Emergency Medicine European Congress 2012--2014; American College of Emergency Physicians Scientific Assembly 2012--2014; Japanese Urological Association Annual Meeting 2015; American Urological Association Annual Meeting 2012--2015) were also searched. A review of further conference proceedings was prevented by a lack of either professional organisation membership or online availability.

Search strategy {#s3d}
---------------

The following search strategy was used on MEDLINE; other database search strategies were comparable. MEDLINE; exp RENAL COLIC/OR exp URINARY CALCULI/OR exp KIDNEY CALCULI/OR exp URETERAL OBSTRUCTION/; 39 880 results.MEDLINE; exp URETERAL CALCULI/; 5353 results.MEDLINE; exp NEPHROLITHIASIS/; 15 880 results.MEDLINE; exp URETEROLITHIASIS/; 5429 results.MEDLINE; (kidney AND stone OR 'kidney stone').ti,ab; 3873 results.MEDLINE; (ureteric AND colic OR 'ureteric colic').ti,ab; 227 results.MEDLINE; 1 OR 2 OR 3 OR 4 OR 5 OR 6; 41 731 results.MEDLINE; exp ALBUTEROL/; 8769 results.MEDLINE; exp TERBUTALINE/; 2963 results.MEDLINE; exp EPHEDRINE/; 4374 results.MEDLINE; exp ISOPROTERENOL/; 28 758 results.MEDLINE; exp DOBUTAMINE/; 5665 results.MEDLINE; exp XAMOTEROL/; 251 results.MEDLINE; exp METAPROTERENOL/; 3160 results.MEDLINE; exp CLENBUTEROL/; 1229 results.MEDLINE; exp RITODRINE/; 916 results.MEDLINE; (bambuterol OR formoterol OR indacaterol OR olodaterol OR salmeterol OR amibegron OR mirabegron OR solabegron OR denopamine OR bitolterol OR levosalbutamol OR ventolin OR ventmax OR salbutamol OR asmasal OR airomir OR 'air salb' OR salpin OR salamol).ti,ab; 9597 results.MEDLINE; 8 OR 9 OR 10 OR 11 OR 12 OR 13 OR 14 OR 15 OR 16 OR 17; 56 523 results.MEDLINE; exp ADRENERGIC BETA-AGONISTS/; 103 561 results.MEDLINE; exp ADRENERGIC BETA-2 RECEPTOR AGONISTS/; 16 296 results.MEDLINE; 18 OR 19 OR 20; 109 820 results.MEDLINE; 7 AND 21; 43 results.

Study selection {#s3e}
---------------

Duplicates were removed using Zotero V.4.0. Citations were imported into Mendeley V.1.13.8 (which was used to manage references for the review); any further duplications reported at this stage were manually verified and merged.

Two investigators independently screened the title, abstract and keywords of every record identified by the search. If either investigator felt a paper merited further review, the full text of the article was examined.

All full-text articles were again reviewed independently by two investigators and assessed for eligibility against the above criteria. Differences in opinion were resolved by discussion; a third investigator would have mediated in the event that any discussions were unsuccessful.

Results {#s4}
=======

The database searches identified 276 records; a further 13 records were found via alternative sources as detailed above. A total of 256 records remained after the removal of duplicates. Following the screening process, four articles were identified for full-text review: Aronson and Hauben;[@R26] Erickson and Lieske;[@R27] Helviz *et al*;[@R28] and Reed.[@R29] Details of the record management process during the review can be seen in [figure 1](#BMJOPEN2016011315F1){ref-type="fig"}.

![PRISMA flow diagram demonstrating record handling during the systematic review.](bmjopen2016011315f01){#BMJOPEN2016011315F1}

None of the articles reviewed at the full-text stage met any of the inclusion criteria for the systematic review. All had titles that did not allow immediate exclusion and three of the four papers did not have abstracts available for review; however, on full-text review, it was found that none of the above articles were clinical trials. Full details of reasons for exclusion can be seen in [table 1](#BMJOPEN2016011315TB1){ref-type="table"}.

###### 

A table of articles excluded after review of the full text

  Full-text articles reviewed with rationale for exclusion   
  ---------------------------------------------------------- ----------------------------------------------------------------------
  Aronson and Hauben[@R26]                                   Not a clinical trial; opinion piece re: adverse drug reactions
  Erickson and Lieske[@R27]                                  Not a clinical trial; topic review of renal calculi
  Helviz *et al*[@R28]                                       Not a clinical trial; case report of symmetrical peripheral gangrene
  Reed[@R29]                                                 Not a clinical trial; drug information re: hormone therapy

Discussion {#s5}
==========

There is a disappointing lack of evidence to inform the use of β-agonists for analgesia in patients with renal colic; no relevant clinical trials were identified despite the broad inclusion criteria applied during the selection process.

There is a clear biological plausibility for the use of β-agonists in renal colic; the available evidence confirms both the presence of β-adrenoreceptors in the human ureter and that their stimulation causes ureteral relaxation. This effect has been demonstrated in vivo,[@R19] although in a different cohort of patients and for a different indication.

One potential explanation for the paucity of evidence on this topic is the recent research focus on the utility of α-adrenoreceptor antagonists in patients with nephrolithiasis. They have previously been thought to reduce stone transit time and the frequency of pain episodes;[@R8] the oral formulation and longer duration of action renders them ideal agents for long-term management and has rightly therefore made them a research focus in the past. However, their use in the emergency department for acute pain control is unfortunately limited by the slow onset time and a lack of evidence of any effect on acute pain; clinical trials have not been powered to detect effects on pain in the acute situation. Recently, significant doubts about their efficacy as expulsive therapies have been raised.[@R30]

Conversely, the potential advantages of β-agonists include their rapid onset time (almost immediate when administered either by the nebulised or intravenous route) and the pre-existing familiarity with their use that exists within acute settings. The potential for both systemic and topical action is also clearly advantageous. Despite some concerns raised within the literature,[@R18] side effects are usually well tolerated[@R31] (especially in the absence of significant comorbidity) and a patient group has suggested that the most common side effects (tremor, tachycardia and restlessness) are likely to be an acceptable trade-off in return for improved analgesia. (Tabner A. Patient and Public Involvement Meeting Summary---SARC, unpublished).

Conclusion {#s6}
==========

There is no evidence to support or refute the proposed use of β-agonists for analgesia in patients with renal colic.

Further research on this topic has been suggested as long ago as 1975.[@R32] β-agonists are cheap, readily available and have predictable, manageable and relatively mild side effects. Given the clinical need, the clear biological plausibility, the animal model evidence and the limited but promising human studies (especially Jung *et al*[@R19]), clinical trials investigating the use of β-agonists in the acute setting for renal colic are recommended.
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